Starpharma Holdings Limited (SPHRY)

Market Cap	119.54M +33.7%
Revenue (ttm)	8.76M +116.5%
Net Income	-5.16M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	0.08 (2.98%)
Ex-Dividend Date	Aug 10, 2026

Volume	1
Open	2.820
Previous Close	3.210
Day's Range	2.820 - 2.820
52-Week Range	2.100 - 5.980
Beta	0.83
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 16, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 50
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPHRY

Financial Performance

In fiscal year 2026, Starpharma Holdings's revenue was 12.67 million, an increase of 116.55% compared to the previous year's 5.85 million. Losses were -7.47 million, -25.28% less than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error